The most extensive analysis of the World Health Organization’s (WHO) database indicated that pericardial disease accounted for 0.3% of all reported toxicities associated with ICIs, with the majority (56%) referring to lung cancer patients receiving anti-PD-1 or anti-PD-L1 therapy after radiotherapy [10]. Here, PDCD1 is linked to lung cancer.